Related Experiment Video
Updated: Nov 10, 2025
05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.0K
Glucose Abnormalities and Inappropriate Weight Gain Predict Negative Pregnancy Outcomes After Gastric Bypass Surgery
H Gohier1, B Guyard-Boileau2, G Tuyeras3
1Nutrition Department, University Hospital Toulouse, CHU de Toulouse, Cedex 09, 31059, Toulouse, France.
Obesity Surgery
|April 2, 2021
Summary
Pregnancies after gastric bypass surgery show high risks for adverse outcomes. Monitoring interstitial glucose and maternal weight gain is crucial for improving outcomes in these high-risk pregnancies.
Area of Science:
- Bariatric surgery outcomes
- Maternal-fetal medicine
- Endocrinology
Background:
- Pregnancy following Roux-en-Y gastric bypass (RYGB) surgery is associated with increased risks of gestational diabetes mellitus, prematurity, and small for gestational age (SGA) infants.
- Understanding interstitial glucose (IG) profiles and maternal weight changes is essential for managing these pregnancies.
Purpose of the Study:
- To describe interstitial glucose (IG) profiles and weight changes during pregnancies after RYGB.
- To investigate the association between IG profiles, weight changes, and adverse pregnancy outcomes.
Main Methods:
- Retrospective analysis of 122 pregnancies post-RYGB.
- Continuous glucose monitoring (CGM) used to evaluate IG profiles.
- Logistic regression analysis to assess the influence of weight gain and IG on outcomes.
Main Results:
- 73% of women exhibited IG abnormalities (high or low glucose levels).
- Adverse outcomes included large for gestational age (LGA) infants (4%), SGA infants (20%), and prematurity (13%).
- Inappropriate maternal weight gain was independently associated with LGA and prematurity.
Conclusions:
- IG abnormalities and maternal weight gain significantly impact neonatal outcomes in pregnancies after RYGB.
- Close monitoring of IG and weight gain is recommended for pregnancies following RYGB surgery.
Related Concept Videos
01:20Pathophysiology of Diabetes
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.3K
01:22Diabetes Mellitus: Type 2 and Gestational
3.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
01:15Diabetes: Symptoms, Diagnosis, and Complications
1.4K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.4K
01:15Hypoglycemia and Glucagon
513
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
513
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
79
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
79
01:27Glucose Transporters
26.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.4K